D-0544-2026 Class II Ongoing

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0544-2026 was initiated by Zydus Pharmaceuticals (USA) Inc on Apr 29, 2026 and is designated Class II. Reason for recall: CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit The recall status is ongoing. Affected quantity: 23,880 bottles.

Recall details

Product Type
Drugs
Report Date
May 27, 2026
Initiation Date
Apr 29, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
23,880 bottles

Product description

Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; a) 30 count bottles (NDC 70710-1047-3); b) 100 count bottles (NDC 70710-1047-1).

Reason for recall

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Distribution pattern

Nationwide within the U.S

Code information

Lots: a) M411146, Expires: 08/2026; M502098, M502097, Expires: 01/2027; b) M411145, Expires: 08/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0544-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0544-2026. Report a data issue: hello@regdatalab.com.